Affordable Access

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.

Authors
  • Patel, Premal H1
  • Kondagunta, G Varuni
  • Schwartz, Lawrence
  • Ishill, Nicole
  • Bacik, Jennifer
  • DeLuca, John
  • Russo, Paul
  • Motzer, Robert J
  • 1 Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Type
Published Article
Journal
Investigational new drugs
Publication Date
Jun 01, 2008
Volume
26
Issue
3
Pages
273–276
Identifiers
PMID: 18161005
Source
Medline
License
Unknown

Abstract

Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial.

Report this publication

Statistics

Seen <100 times